Cingulate Inc. 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Cingulate Inc. on October 7, 2024. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Kansas City, KS. Its common stock (CING) and warrants (CINGW) trade on the Nasdaq Capital Market.
Key Financial Metrics
- Cash Raised: Approximately $11.7 million raised during August and September 2024.
- Cash Position: Approximately $10 million in cash and cash equivalents as of September 30, 2024.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, profit, or margins.
- Debt and Liquidity: Specific debt figures are not disclosed; liquidity is supported by the recent capital raise and existing cash balance.
Material Changes and Outlook
The primary material event is the successful capital raise of $11.7 million. Management states this funding extends the Company's cash runway to cover clinical, manufacturing, regulatory activities, and operating costs through the second quarter of 2025. The Company targets the filing of a New Drug Application (NDA) for its candidate CTx-1301 with the FDA in mid-2025.
Risks and Contingencies
The filing does not explicitly detail new risks or contingencies beyond the standard operational reliance on the funded runway to reach the mid-2025 NDA filing milestone.
Investor Verification Checklist
- Verify the exact closing dates and terms of the $11.7 million capital raise.
- Confirm the specific burn rate implied by the runway extending to Q2 2025.
- Monitor progress toward the mid-2025 NDA filing for CTx-1301.
- Review subsequent filings for any updates to the $10 million cash balance as of September 30, 2024.